The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | M | Musculo-skeletal system | |
| 2 | M05 | Drugs for treatment of bone diseases | |
| 3 | M05B | Drugs affecting bone structure and mineralization | |
| 4 | M05BA | Bisphosphonates | |
| 5 | M05BA04 | Alendronic acid |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 10 mg |
| Active Ingredient | Description | |
|---|---|---|
| Alendronic acid |
Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BINOSTO Effervescent tablet | Marketing Authorisation Holder | MPI, EU: SmPC | |
| DENSATE Tablet | Marketing Authorisation Holder | MPI, Generic | |
| Fosamax | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| FOSAMAX Once Weekly Tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
